FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway

Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs. Here, we found ovarian cancer patients with low FAM83B levels had shorter survival time, tissues with cisplatin resistance also...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Shanyang, Wang, Wei, Wan, Zhiyong, Shen, Hongwei, Zhao, Yunhe, You, Zeshan, Liu, Jun, Zhu, Liwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797002/
https://www.ncbi.nlm.nih.gov/pubmed/33423038
http://dx.doi.org/10.1038/s41389-020-00301-y
_version_ 1783634780410085376
author He, Shanyang
Wang, Wei
Wan, Zhiyong
Shen, Hongwei
Zhao, Yunhe
You, Zeshan
Liu, Jun
Zhu, Liwen
author_facet He, Shanyang
Wang, Wei
Wan, Zhiyong
Shen, Hongwei
Zhao, Yunhe
You, Zeshan
Liu, Jun
Zhu, Liwen
author_sort He, Shanyang
collection PubMed
description Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs. Here, we found ovarian cancer patients with low FAM83B levels had shorter survival time, tissues with cisplatin resistance also had low FAM83B levels, suggesting FAM83B might inhibit cisplatin resistance. FAM83B overexpression inhibits cisplatin resistance showed in increased ovarian cancer cell proliferation and growth rate, and reduced apoptosis rate, while FAM83B knockdown promotes cisplatin resistance. Mechanism analysis showed FAM83B interacted with APC to inhibit Wnt pathway activity, causing ovarian cancer cisplatin resistance. We also found FAM83B levels were negative with Wnt pathway activity in clinic samples, confirming FAM83B inhibited Wnt pathway activity. In summary, we found FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway, providing a new target for ovarian cancer therapy.
format Online
Article
Text
id pubmed-7797002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77970022021-01-21 FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway He, Shanyang Wang, Wei Wan, Zhiyong Shen, Hongwei Zhao, Yunhe You, Zeshan Liu, Jun Zhu, Liwen Oncogenesis Article Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs. Here, we found ovarian cancer patients with low FAM83B levels had shorter survival time, tissues with cisplatin resistance also had low FAM83B levels, suggesting FAM83B might inhibit cisplatin resistance. FAM83B overexpression inhibits cisplatin resistance showed in increased ovarian cancer cell proliferation and growth rate, and reduced apoptosis rate, while FAM83B knockdown promotes cisplatin resistance. Mechanism analysis showed FAM83B interacted with APC to inhibit Wnt pathway activity, causing ovarian cancer cisplatin resistance. We also found FAM83B levels were negative with Wnt pathway activity in clinic samples, confirming FAM83B inhibited Wnt pathway activity. In summary, we found FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway, providing a new target for ovarian cancer therapy. Nature Publishing Group UK 2021-01-09 /pmc/articles/PMC7797002/ /pubmed/33423038 http://dx.doi.org/10.1038/s41389-020-00301-y Text en © The Author(s) 2021, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
He, Shanyang
Wang, Wei
Wan, Zhiyong
Shen, Hongwei
Zhao, Yunhe
You, Zeshan
Liu, Jun
Zhu, Liwen
FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title_full FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title_fullStr FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title_full_unstemmed FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title_short FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway
title_sort fam83b inhibits ovarian cancer cisplatin resistance through inhibiting wnt pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797002/
https://www.ncbi.nlm.nih.gov/pubmed/33423038
http://dx.doi.org/10.1038/s41389-020-00301-y
work_keys_str_mv AT heshanyang fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT wangwei fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT wanzhiyong fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT shenhongwei fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT zhaoyunhe fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT youzeshan fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT liujun fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway
AT zhuliwen fam83binhibitsovariancancercisplatinresistancethroughinhibitingwntpathway

Ejemplares similares